Drugs / C20T5
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05615389 | Feb 2024 → Oct 2026 expected | — | Murdoch Childrens Research Institute | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | C20T5 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05615389 ↗ |
| Known as | Ruby CBD Oil | “C20T5 Ruby CBD Oil (Cannatrek Ltd, Australia).” NCT05615389 ↗ |
| Route | Oral | “two different oral MC oil formulations” NCT05615389 ↗ |